You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Dow
Mallinckrodt

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

ZARONTIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Zarontin, and when can generic versions of Zarontin launch?

Zarontin is a drug marketed by Parke Davis and Parke-davis and is included in two NDAs.

The generic ingredient in ZARONTIN is ethosuximide. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the ethosuximide profile page.

US ANDA Litigation and Generic Entry Outlook for Zarontin

A generic version of ZARONTIN was approved as ethosuximide by PHARM ASSOC on November 22nd, 2000.

  Start Trial

Drug patent expirations by year for ZARONTIN
Drug Prices for ZARONTIN

See drug prices for ZARONTIN

Recent Clinical Trials for ZARONTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zhejiang UniversityEarly Phase 1
Fondation ApicilPhase 2
University Hospital, Clermont-FerrandPhase 2

See all ZARONTIN clinical trials

US Patents and Regulatory Information for ZARONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis ZARONTIN ethosuximide CAPSULE;ORAL 012380-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Parke-davis ZARONTIN ethosuximide SYRUP;ORAL 080258-001 Approved Prior to Jan 1, 1982 AA RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Dow
Express Scripts
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.